- Home
- LRE vs BCAB Comparison
LRE vs BCAB Comparison
Compare LRE & BCAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LRE
- BCAB
- Stock Information
- Founded
- LRE 2001
- BCAB 2007
- Country
- LRE Japan
- BCAB United States
- Employees
- LRE N/A
- BCAB N/A
- Industry
- LRE
- BCAB Medicinal Chemicals and Botanical Products
- Sector
- LRE
- BCAB Health Care
- Exchange
- LRE Nasdaq
- BCAB Nasdaq
- Market Cap
- LRE 22.5M
- BCAB 27.0M
- IPO Year
- LRE 2023
- BCAB 2020
- Fundamental
- Price
- LRE $1.35
- BCAB $0.41
- Analyst Decision
- LRE
- BCAB Buy
- Analyst Count
- LRE 0
- BCAB 2
- Target Price
- LRE N/A
- BCAB $5.00
- AVG Volume (30 Days)
- LRE 5.3K
- BCAB 834.0K
- Earning Date
- LRE 01-01-0001
- BCAB 03-25-2025
- Dividend Yield
- LRE N/A
- BCAB N/A
- EPS Growth
- LRE N/A
- BCAB N/A
- EPS
- LRE 0.29
- BCAB N/A
- Revenue
- LRE $117,804,154.00
- BCAB $11,000,000.00
- Revenue This Year
- LRE N/A
- BCAB N/A
- Revenue Next Year
- LRE N/A
- BCAB N/A
- P/E Ratio
- LRE $4.61
- BCAB N/A
- Revenue Growth
- LRE 8.82
- BCAB N/A
- 52 Week Low
- LRE $1.19
- BCAB $0.38
- 52 Week High
- LRE $13.76
- BCAB $4.02
- Technical
- Relative Strength Index (RSI)
- LRE 30.61
- BCAB 32.49
- Support Level
- LRE $1.20
- BCAB $0.42
- Resistance Level
- LRE $1.70
- BCAB $0.50
- Average True Range (ATR)
- LRE 0.10
- BCAB 0.05
- MACD
- LRE -0.02
- BCAB 0.02
- Stochastic Oscillator
- LRE 25.89
- BCAB 20.97
About LRE Lead Real Estate Co. Ltd
Lead Real Estate Co Ltd operates as a developer of luxury residential properties, including single-family homes and condominiums, across Tokyo, Kanagawa prefecture, and Sapporo. The company also operates hotels in Tokyo and leases apartment building units to individual customers in Japan and Dallas, Texas. Predominantly, its revenue is generated from developing and selling single-family homes and condominiums. The company's sole operating segment is real estate sales. Geographically, it derives revenue from Japan.
About BCAB BioAtla Inc.
BioAtla Inc is a clinical-stage biopharmaceutical company. The company is engaged in the development of a novel class of specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. Its pipeline products comprise mecbotamab vedotin (BA3011), ozuriftamab vedotin (BA3021), and evalstotug (BA3071), and its Phase 1 clinical trial of BA3182 (CAB-EpCAM x CAB-CD3) and Bispecific antibody programs.